ASKA Pharmaceutical Holdings ,Ltd. Receivables

ASKA Pharmaceutical Holdings ,Ltd. posts a receivables of $17B as of June 2026. That compares with $16B in the prior-year period — up 3.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, ASKA Pharmaceutical Holdings ,Ltd.'s receivables was $16B. The latest reading is $17B — a 3.1% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of ASKA Pharmaceutical Holdings ,Ltd.'s financial statement story. At $17B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 4886.T's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; ASKA Pharmaceutical Holdings ,Ltd.'s other metric pages and overview cover the third.